Insider buy in...With over $11 million cash CZO is choosing its pipeline assets to invest in. It doesn't have to. It could drop any one of the pipeline assets. It could move in an entirely different direction. All pipeline assets are moving to the next stage from clinical trial to scale-up in CZO's biggest spending program in its history. Again, if they didn't beleive in any of the projects they could drop it given the multi-asset pipeline and ability to move in a totally different direction. Insiders will make money from their options, etc., if these programs are successful. They have an interest in the outcomes. CZO is also pursuing uplisting opportunities ot NASDAQ as it prepares for the next stage as a biopharma. The next stage in CZO's evolution is near at hand.